Three key potential targets are illustrated in Figure 1C; TAU (MAPT) for its integral association with Alzheimer’s disease neurodegeneration, ERK1 (MAPK3) already demonstrated to be regulated by miR-483-5p and ERK2 (MAPK1) for its similarity to ERK1 and the promising context++ score. This evidence concerns the gene MAPK1 and early-onset autosomal dominant Alzheimer disease.